Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: Results from an open-label and from a randomised study

BMC Pharmacology and Toxicology

Volumn 14, Issue , 2013, Pages

  Cahn, Anthony ^a   Hodgson, Simon ^a   Wilson, Robert ^a   Robertson, Jonathan ^a   Watson, Joanna ^b   Beerahee, Misba ^a   Hughes, Steve C ^b   Young, Graeme ^b   Graves, Rebecca ^a   Hall, David ^a   van Marle, Sjoerd ^c   Solari, Roberto ^a  

^a Medicines Discovery and Development   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c PRA Health Sciences   (Netherlands)

Author keywords

CCR4; GSK2239633; Healthy; Microdose

Indexed keywords

ACTIN; CHEMOKINE RECEPTOR CCR ANTAGONIST; CHEMOKINE RECEPTOR CCR4; GSK 2239633; PLACEBO; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG; INDAZOLE DERIVATIVE; N-((3-((3-(((5-CHLORO-2-THIENYL)SULFONYL)AMINO)-4-(METHYLOXY)-1H-INDAZOL-1-YL)METHYL)PHENYL)METHYL)-2-HYDROXY-2-METHYLPROPANAMIDE; SULFONAMIDE;

ABDOMINAL PAIN; ACTIN POLYMERIZATION; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG MICRODOSE; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PHARMACODYNAMICS; PHARMACOKINETICS; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SAFETY; TIME TO MAXIMUM PLASMA CONCENTRATION; AGED; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

ABDOMINAL PAIN; ADMINISTRATION, ORAL; ADULT; AGED; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HEADACHE; HUMANS; INDAZOLES; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; RECEPTORS, CCR4; RHINITIS; SULFONAMIDES; YOUNG ADULT;

EID: 84880582202     PISSN: 20506511     EISSN: None     Source Type: Journal    
DOI: 10.1186/2050-6511-14-14     Document Type: Article

References (41)

1. Finiasz M, Otero C, Bezrodnik L, Fink S. The role of cytokines in atopic asthma. Curr Med Chem 2011, 18:1476-1487. 10.2174/092986711795328346, 21428894.
2. Pease JE. Targeting Chemokine receptors in allergic disease. Biochem J 2011, 434:11-24. 10.1042/BJ20101132, 21269275.
3. Azzawi M, Bradley B, Jeffery PK, Frew AJ, Wardlaw AJ, Knowles G, Assoufi B, Collins JV, Durham S, Kay AB. Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am Rev Respir Dis 1990, 142:1407-1413.
4. Fanta CH. Asthma. N Engl J Med 2009, 360:1002-1014. 10.1056/NEJMra0804579, 19264689.
5. Hamid Q, Tulic M. Immunobiology of asthma. Annu Rev Physiol 2009, 71:489-507. 10.1146/annurev.physiol.010908.163200, 19575684.
6. Long AA. Immunomodulators in the treatment of asthma. Allergy Asthma Proc 2009, 30:109-119. 10.2500/aap.2009.30.3203, 19463201.
7. Minai-Fleminger Y, Levi-Schaffer F. Mast cells and eosinophils: the two key effector cells in allergic inflammation. Inflamm Res 2009, 58:631-638. 10.1007/s00011-009-0042-6, 19440657.
8. Vestergaard C, Yoneyama H, Murai M, Nakamura K, Tamaki K, Terashima Y, Imai T, Yoshie O, Irimura T, Mizutani H, Matsushima K. Overproduction of Th2-specific Chemokines in NC/Nga mice exhibiting atopic dermatitis-like lesions. J Clin Invest 1999, 104:1097-1157. 10.1172/JCI7613, 408579, 10525048.
9. Vestergaard C, Bang K, Gesser B, Yoneyama H, Matsushima K, Larsen CG. A Th2 Chemokine, TARC, produced by keratinocytes may recruit CLA + CCR4+ lymphocytes into lesional atopic dermatitis skin. J Invest Dermatol 2000, 115:640-646. 10.1046/j.1523-1747.2000.00115.x, 10998136.
10. Sekiya T, Miyamasu M, Imanishi M, Yamada H, Nakajima T, Yamaguchi M, Fujisawa T, Pawankar R, Sano Y, Ohta K, Ishii A, Morita Y, Yamamoto K, Matsushima K, Yoshie O, Hirai K. Inducible expression of a Th2-type CC Chemokine thymus- and activation-regulated Chemokine by human bronchial epithelial cells. J Immunol 2000, 165:2205-2213.
11. Zheng X, Nakamura K, Furukawa H, Nishibu A, Takahashi M, Tojo M, Kaneko F, Kakinuma T, Tamaki K. Demonstration of TARC and CCR4 mRNA expression and distribution using in situ RT-PCR in the lesional skin of atopic dermatitis. J Dermatol 2003, 30:26-32.
12. Liu YJ. Thymic stromal lymphopoietin: master switch for allergic inflammation. J Exp Med 2006, 203:269-273. 10.1084/jem.20051745, 2118215, 16432252.
13. Imai T, Baba M, Nishimura M, Kakizaki M, Takagi S, Yoshie O. The T cell-directed CC Chemokine TARC is a highly specific biological ligand for CC Chemokine receptor 4. J Biol Chem 1997, 272:15036-15042. 10.1074/jbc.272.23.15036, 9169480.
14. Imai T, Chantry D, Raport CJ, Wood CL, Nishimura M, Godiska R, Yoshie O, Gray PW. Macrophage-derived Chemokine is a functional ligand for the CC Chemokine receptor 4. J Biol Chem 1998, 273:1764-1768. 10.1074/jbc.273.3.1764, 9430724.
15. Imai T, Nagira M, Takagi S, Kakizaki M, Nishimura M, Wang J, Gray PW, Matsushima K, Yoshie O. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC Chemokines thymus and activation-regulated Chemokine and macrophage-derived Chemokine. Int Immunol 1999, 11:81-88. 10.1093/intimm/11.1.81, 10050676.
16. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of Chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998, 187:875-883. 10.1084/jem.187.6.875, 2212187, 9500790.
17. D'Ambrosio D, Iellem A, Bonecchi R, Mazzeo D, Sozzani S, Mantovani A, Sinigaglia F. Selective up-regulation of Chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J Immunol 1998, 161:5111-5115.
18. Bochner BS, Hudson SA, Xiao HQ, Liu MC. Release of both CCR4-active and CXCR3-active Chemokines during human allergic pulmonary late-phase reactions. J Allergy Clin Immunol 2003, 112:930-934. 10.1016/j.jaci.2003.08.012, 14610482.
19. Pilette C, Francis JN, Till SJ, Durham SR. CCR4 Ligands are up-regulated in the airways of atopic asthmatics after segmental allergen challenge. Eur Respir J 2004, 23:876-884. 10.1183/09031936.04.00102504, 15219001.
20. Panina-Bordignon P, Papi A, Mariani M, Di Lucia P, Casoni G, Bellettato C, Buonsanti C, Miotto D, Mapp C, Villa A, Arrigoni G, Fabbri LM, Sinigaglia F. The C-C Chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. J Clin Invest 2001, 107:1357-1364. 10.1172/JCI12655, 209325, 11390417.
21. Morgan AJ, Symon FA, Berry MA, Pavord ID, Corrigan CJ, Wardlaw AJ. IL-4-expressing bronchoalveolar T cells from asthmatic and healthy subjects preferentially express CCR 3 and CCR 4. J Allergy Clin Immunol 2005, 116:594-600. 10.1016/j.jaci.2005.03.052, 16159629.
22. Vijayanand P, Durkin K, Hartmann G, Morjaria J, Seumois G, Staples KJ, Hall D, Bessant C, Bartholomew M, Howarth PH, Friedmann PS, Djukanovic R. Chemokine receptor 4 plays a key role in T cell recruitment into the airways of asthmatic patients. J Immunol 2010, 184:4568-4574. 10.4049/jimmunol.0901342, 20237293.
23. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008, 8:183-192. 10.1038/nri2254, 18274560.
24. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008, 118:3546-3556. 10.1172/JCI36130, 2575722, 18982161.
25. Donnelly LE, Barnes PJ. Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends Pharmacol Sci 2006, 27:546-553. 10.1016/j.tips.2006.08.001, 16911834.
26. Hall D, Ford A, Hodgson S. Therapeutic potential of CCR4 antagonists. New drugs and targets for asthma and COPD. Volume 39 2010, 161-165. Karger: Prog Respir Res Basel.
27. Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, Yamaguchi K, Yamada Y, Hanada S, Tamura K, Nakamura S, Inagaki H, Ohshima K, Kiyoi H, Ishida T, Matsushima K, Akinaga S, Ogura M, Tomonaga M, Ueda R. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010, 28:1591-1598. 10.1200/JCO.2009.25.3575, 20177026.
28. Procopiou PA, Ford AJ, Graves RH, Hall DA, Hodgson ST, Lacroix YM, Needham D, Slack RJ. Lead optimisation of the N1 substituent of a novel series of indazole arylsulfonamides as CCR4 antagonists and identification of a candidate for clinical investigation. Bioorg Med Chem Lett 2012, 22:2730-2733. 10.1016/j.bmcl.2012.02.104, 22437117.
29. Hodgson ST, Lacroix YML, Procopiou PA. US patent 2010216860A1 2010, : , http://www.google.co.uk/patents?hl=en&lr=&vid=USPATAPP12711283&id=5OrUAAAAEBAJ&oi=fnd&dq=hodgson+patent+ccr4&printsec=abstract#v=onepage&q=hodgson%20patent%20ccr4&f=false.
30. ICH M3 (R2) - guideline on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002941.pdf.
31. World Medical Association Declaration of Helsinki - ethical principles for medical research involving human subjects http://www.wma.net/en/30publications/10policies/b3, World Medical Association.
32. Paton WDM. A theory of drug action based on the rate of drug-receptor combination. Proc R Soc Lond B 1961, 154:21-69.
33. Banfield G, Watanabe H, Scadding G, Jacobson MR, Till SJ, Hall DA, Robinson DS, Lloyd CM, Nouri-Aria KT, Durham SR. CC Chemokine receptor 4 (CCR4) in human allergen-induced late nasal responses. Allergy 2010, 65:1126-1133. 3380530, 20148806.
34. Nakagami Y, Kawashima K, Yonekubo K, Etori M, Jojima T, Miyazaki S, Sawamura R, Hirahara K, Nara F, Yamashita M. Novel CC Chemokine receptor 4 antagonist RS-1154 inhibits ovalbumin-induced ear swelling in mice. Eur J Pharmacol 2009, 624:38-44. 10.1016/j.ejphar.2009.09.058, 19818758.
35. Nakagami Y, Kawase Y, Yonekubo K, Nosaka E, Etori M, Takahashi S, Takagi N, Fukuda T, Kuribayashi T, Nara F, Yamashita M. RS-1748, a novel CC Chemokine receptor 4 antagonist, inhibits ovalbumin-induced airway inflammation in guinea pigs. Biol Pharm Bull 2010, 33:1067-1079. 10.1248/bpb.33.1067, 20522980.
36. Sato T, Komai M, Iwase M, Kobayashi K, Tahara H, Ohshima E, Arai H, Miki I. Inhibitory effect of the new orally active CCR4 antagonist K327 on CCR4 + CD4+ T cell migration into the lung of mice with ovalbumin-induced lung allergic inflammation. Pharmacology 2009, 84:171-182. 10.1159/000235748, 19713720.
37. Catley MC, Coote J, Bari M, Tomlinson KL. Monoclonal antibodies for the treatment of asthma. Pharmacol Ther 2011, 132:333-351. 10.1016/j.pharmthera.2011.09.005, 21944943.
38. Bayry J, Tchilian EZ, Davies MN, Forbes EK, Draper SJ, Kaveri SV, Hill AV, Kazatchkine MD, Beverley PC, Flower DR, Tough DF. In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc Natl Acad Sci USA 2008, 105:10221-10226. 10.1073/pnas.0803453105, 2481334, 18621704.
39. Davies MN, Bayry J, Tchilian EZ, Vani J, Shaila MS, Forbes EK, Draper SJ, Beverley PC, Tough DF, Flower DR. Toward the discovery of vaccine adjuvants: coupling in silico screening and in vitro analysis of antagonist binding to human and mouse CCR4 receptors. PLoS One 2009, 4:e8084. 10.1371/journal.pone.0008084, 2787246, 20011659.
40. Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E, Badoual C, Gey A, Ravel P, Marcheteau E, Batteux F, Sandoval F, Adotevi O, Chiu C, Garcia S, Tanchot C, Lone YC, Ferreira LC, Nelson BH, Hanahan D, Fridman WH, Johannes L, Tartour E. A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens. Blood 2011, 118:4853-4862. 10.1182/blood-2011-01-329656, 21908423.
41. Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 2007, 13:108-116. 10.1016/j.molmed.2007.01.003, 17257897.